SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila to initiate global pivotal Phase 2(b)/3 clinical trial of Saroglitazar Mg in PBC

10 Dec 2021 Evaluate

Zydus Cadila has received permission from the U.S. Food and Drug Administration (USFDA) to initiate the Phase 2(b)/3 Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled adaptive clinical trial to evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis (PBC).

The EPICS-III trial will randomise 192 subjects in a 1:1:1 ratio to Saroglitazar 1 mg, Saroglitazar 2 mg or Placebo and will study the Saroglitazar Magnesium (1 or 2 mg) relative to Placebo based on the composite endpoints of Alkaline Phosphatase (ALP),total bilirubin, liver stiffness measurement (LSM) by FibroScan, liver enzyme parameters (ALT, AST, GGT, total bilirubin, and albumin), lipid parameters (TG, LDL-C, HDL-C, VLDL-C, total cholesterol, and non-HDL-C), health related quality of life using PBC 40 questionnaire (a patient-derived, disease specific quality of life measure developed and validated for use in PBC) and other outcome measures over a period of 52 weeks.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

1166.00 17.95 (1.56%)
07-Jul-2026 11:02 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1913.10
Dr. Reddys Labs. 1367.00
Cipla 1463.40
Zydus Lifesciences 1166.00
Lupin 2494.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: